Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth

For 3Q25, Syndax Pharmaceuticals ( SNDX ) posted a GAAP EPS loss of –$0.70, which beat estimates by $0.04. Revenue came in at roughly $45.9 million, missing expectations slightly by $2.07 million despite a decent 267% year-over-year increase, which was mainly driven byI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. T ...